Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,291.34 +7.94 (+0.15%) Dow
38,711.29 +140.29 (+0.36%) Nasdaq
16,857.05 +28.35 (+0.17%) Bitcoin USD
70,753.41 +1,727.35 (+2.50%) CMC Crypto 200
1,475.10 +27.95 (+1.93%)
BeiGene, Ltd. (6160.HK)
| Previous close | 87.000 |
| Open | 87.600 |
| Bid | 89.650 x 0 |
| Ask | 89.700 x 0 |
| Day's range | 87.600 - 90.000 |
| 52-week range | 75.450 - 139.900 |
| Volume | |
| Avg. volume | 1,421,041 |
| Market cap | 127.333B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SAN MATEO, Calif., June 04, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT.
- GlobeNewswire
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD
- Business Wire
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
SAN MATEO, Calif., May 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton’s tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphoc
